कंपनी का अवलोकन
CG Oncology, Inc. is a late-stage clinical biopharmaceutical enterprise focused on the development and commercialization of cretostimogene grenadenorepvec for treating bladder cancer patients within the United States market. The company operates within the Healthcare sector, specifically functioning in the Biotechnology industry, which typically involves high-risk research and development activities aimed at creating novel therapeutic products. As of the latest available data, the company's total market capitalization stands at $5.79B, while its annual revenue (TTM) is recorded at $4.04M, supported by a workforce of 142 employees. The valuation figure of $5.79B relative to the modest revenue of $4.04M indicates a significant market premium often associated with late-stage biotech assets that possess promising clinical pipelines but have not yet generated substantial commercial income. This disparity between market cap and revenue highlights the market's pricing of future potential and regulatory approval prospects rather than current operational profitability. The scale of the enterprise, measured by its employee count and capitalization, reflects an organization in a critical growth phase where substantial resources are allocated to advancing investigational oncolytic immunotherapies toward commercial readiness.
वित्तीय स्वास्थ्य
The company reported a revenue of $4.04M (TTM) alongside a net income of $-160,995,008 and an EBITDA of $-189,328,992, revealing a substantial gap between top-line generation and bottom-line earnings. This wide divergence between revenue and net income underscores an aggressive cost structure or significant investment in research and development that has not yet been offset by profitable operations. The free cash flow stands at $-87,615,752, indicating that the company is currently burning cash to fund its operations and development efforts rather than generating liquidity for shareholders. Despite the negative cash flow, the balance sheet holds $742.16M in cash against a relatively low debt load of $7.02M, suggesting a strong liquidity position to support ongoing expenditures. The gross margin is recorded at 0.0%, while the operating margin is -2097.3% and the profit margin is 0.0%, figures that collectively indicate the company is not yet profitable and is operating at a loss on both gross and operating levels. The return on equity is -21.7% and the return on assets is -15.4%, metrics that demonstrate the company is currently destroying value from the perspective of shareholders and asset holders due to its negative earnings. The debt-to-equity ratio of 0.93 combined with a current ratio of 24.63 suggests that while the company carries some leverage, its short-term liquidity is extremely robust, allowing it to meet obligations with a large buffer.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A, while the forward P/E ratio is -34.41, a difference that implies the market is valuing the company based on anticipated future earnings rather than current profitability. The price-to-book ratio is 7.35, which indicates that the stock is trading at a significant premium over its net asset value, a common characteristic of biotech firms with valuable intellectual property. The price-to-sales ratio stands at 1432.89 and the EV/EBITDA is -26.69, alternative valuation metrics that suggest the market is placing a very high multiple on sales due to expectations of future commercial success upon regulatory approval. The 52-week high is $69.35 and the 52-week low is $14.80, meaning the current trading price sits somewhere within this wide range, reflecting the high volatility typical of small-cap biotechnology stocks. The beta value is 0.70, indicating that the stock's price volatility is lower than the broader market, which is somewhat unusual for a company with such a high price-to-sales multiple and suggests less sensitivity to general market movements compared to large-cap equities.
Growth & Income
The revenue growth (YoY) is 409.2%, while the earnings growth (YoY) is N/A, indicating that the company has not yet achieved positive earnings to measure growth in that metric. The absence of earnings growth data alongside the massive revenue expansion implies that the rapid top-line growth is driven by commercialization or sales increases rather than profit scaling. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the company retains all its earnings to reinvest into research, development, and commercialization efforts. This reinvestment strategy is standard for late-stage biopharmaceutical companies that prioritize funding their clinical trials and market expansion over returning capital to shareholders via dividends. The overall growth and income profile is characterized by exceptional revenue expansion paired with significant cash burn and a lack of current profitability or dividend income.